EpiPen(R), the leading auto-injector product, is on track to become a billion dollar product in 2014 according to its distributor Mylan Inc. In 2013, G2B Pharma and SNBL (Japan) conducted a successful proof of concept study which showed that nasally administered G2B011 demonstrates rapid and high absorption comparable to EpiPen(R), and has the potential to…